{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:23Z","timestamp":1790173343640,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ygyno.2011.11.050","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T22:04:12Z","timestamp":1323381852000},"page":"65-69","source":"Crossref","is-referenced-by-count":52,"title":["Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125"],"prefix":"10.1016","volume":"125","author":[{"given":"Mich\u00e8l","family":"Schummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingegerd","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Erik","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.11.050_bb0005","unstructured":"[No authors listed] (2000) Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database of Systematic Reviews Issue 1: Art No: CD001418."},{"key":"10.1016\/j.ygyno.2011.11.050_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0020","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/00365510050216448","article-title":"Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer","volume":"60","author":"Tuxen","year":"2000","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/003655102317475434","article-title":"Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up","volume":"62","author":"Tuxen","year":"2002","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0045","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0050","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0140-6736(10)61515-2","article-title":"Ovarian cancer: relevant therapy, not timing, is paramount","volume":"376","author":"Morris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/era.10.204","article-title":"Timing for starting second-line therapy in recurrent ovarian cancer","volume":"11","author":"Guarneri","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0060","first-page":"5","article-title":"CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"5","author":"Fleming","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0065","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0080","article-title":"Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer","volume":"26","author":"Allard","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17530059.2011.559459","article-title":"Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma","volume":"5","author":"Hellstr\u00f6m","year":"2011","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0090","doi-asserted-by":"crossref","first-page":"e2633","DOI":"10.1371\/journal.pone.0002633","article-title":"Systematic evaluation of candidate blood markers for detecting ovarian cancer","volume":"3","author":"Palmer","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0095","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-05-2007","article-title":"Bead-based ELISA for validation of ovarian cancer early detection markers","volume":"12","author":"Scholler","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-10-0193","article-title":"A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer","volume":"4","author":"Zhu","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0115","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0120","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1055-9965.EPI-08-0039","article-title":"Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients","volume":"17","author":"Hellstr\u00f6m","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0130","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1158\/1078-0432.CCR-07-1442","article-title":"Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA","volume":"14","author":"Scholler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0140","article-title":"Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer","author":"Park","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0145","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","article-title":"Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases","volume":"44","author":"Park","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0b013e31821a3726","article-title":"Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma","author":"Chang","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0160","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-08-0150","article-title":"Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer","volume":"17","author":"Lowe","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0175","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.25203","article-title":"CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease","volume":"116","author":"Bast","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0185","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1200\/jco.2008.26.15_suppl.5535","article-title":"Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer","volume":"26","author":"Allard","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0190","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1158\/1055-9965.EPI-08-1034","article-title":"Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125","volume":"18","author":"Shah","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2011.11.050_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejogrb.2011.05.021","article-title":"Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer","author":"Paek","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T02:28:34Z","timestamp":1543372114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811009735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090825811009735"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.050","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}